Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...
Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...
Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback